Showing results (1-10 of 56) with videos related to
Sort By:
Pageof 6
Current Oncology (Toronto, Ont.)|February 26, 2026
SMARCA4-Deficient Carcinomas of the Small Intestine: A Systematic ReviewAaqid Syed, Yanis Boumber, Midhun MallaFrontiers in Oncology|July 7, 2025
HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalitiesAhmed Ismail, Aakash Desai, Yanis BoumberOncology (Williston Park, N.Y.)|May 10, 2011
Epigenetics in cancer: what's the future?Yanis Boumber, Jean-Pierre J IssaCureus|December 25, 2025
Sarcoidosis With Isolated Osseous Manifestations Mimicking Metastatic MalignancyAhmed Ismail, Ahmed Saleh, Yanis BoumberCancer|November 7, 2019
Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC)J Nicholas Bodor, Yanis Boumber, Hossein BorghaeiExpert Opinion on Investigational Drugs|May 11, 2011
Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitorYanis Boumber, Anas Younes, Guillermo Garcia-ManeroBiomolecules|May 27, 2026
Antibody-Drug Conjugates Beyond HER2 in Non-Small Cell Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future DirectionsAhmed Ismail, Aakash Desai, George R Simon, et al.Cancers|June 26, 2026
Baseline Lymphopenia Predicts Survival in ICI-Naïve Solid Tumor Patients Receiving Immune Checkpoint Inhibitors: A Propensity-Matched Real-World Pan-Cancer AnalysisAhmed Ismail, Nina Balanchivadze, George R Simon, et al.Future Oncology (London, England)|July 29, 2016
The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hopePranshu Bansal, Chad Rusthoven, Yanis Boumber, et al.BMC Cancer|April 26, 2019
Case report: reinitiating pembrolizumab treatment after small bowel perforationTim N Beck, Alexander E Kudinov, Essel Dulaimi, et al.Pageof 6